Status:
COMPLETED
Sarcopenia and Diabetes Mellitus
Lead Sponsor:
Dionyssiotis, Yannis, M.D.
Collaborating Sponsors:
University of Thessaly
Conditions:
Sarcopenia
Eligibility:
All Genders
20-80 years
Brief Summary
The association of diabetes mellitus type 2 (T2DM) with sarcopenia has not been adequately investigated. Sarcopenia is characterized by progressive and generalized loss of skeletal muscle mass which m...
Detailed Description
The relationship between DM and sarcopenia has not been extensively investigated. Skeletal muscle is the primary site of glucose deposition, and decreased muscle mass plays a role in impaired glucose ...
Eligibility Criteria
Inclusion
- T2DM participants were on treatment with oral hypoglycemic agents
- confirmation criteria of a T2DM diagnosis were glycosylated hemoglobin A1c levels ≥ 6.5% and fasting plasma glucose ≥ 126 mg/dl (7 mmol/l).
Exclusion
- history of a cerebrovascular event, a heart stent, an artificial cardiac pacemaker or other metallic implant,
- a malignant tumor, liver disease, end stage chronic kidney disease, a thyroid disorder, carpal tunnel syndrome,
- subjects who received special dietary supplements such as protein powder, during the last three months were excluded from the study.
Key Trial Info
Start Date :
March 20 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 22 2018
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT04407819
Start Date
March 20 2018
End Date
September 22 2018
Last Update
May 29 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Foundation for Care of Neurological Illnesses, Greece
Athens, Attica, Greece, 11256